MET and neoplasm: In previous studies, MET amplification was identified as the main molecular alteration associated with the first-line treatment failure of osimertinib, occurring in 7.4% (2/27),15 9.5% (2/21),21 14.8% (4/27),22 and 19.6% (9/46)23 of patients by tumor tissue detection.